Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance.

Rivadeneira DB, DePeaux K, Wang Y, Kulkarni A, Tabib T, Menk AV, Sampath P, Lafyatis R, Ferris RL, Sarkar SN, Thorne SH, Delgoffe GM.

Immunity. 2019 Sep 17;51(3):548-560.e4. doi: 10.1016/j.immuni.2019.07.003. Epub 2019 Aug 27.

PMID:
31471106
2.

Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date.

Zavras PD, Wang Y, Gandhi A, Lontos K, Delgoffe GM.

Onco Targets Ther. 2019 Jun 11;12:4543-4554. doi: 10.2147/OTT.S177844. eCollection 2019. Review.

3.

Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ.

Liu C, Chikina M, Deshpande R, Menk AV, Wang T, Tabib T, Brunazzi EA, Vignali KM, Sun M, Stolz DB, Lafyatis RA, Chen W, Delgoffe GM, Workman CJ, Wendell SG, Vignali DAA.

Immunity. 2019 Aug 20;51(2):381-397.e6. doi: 10.1016/j.immuni.2019.06.017. Epub 2019 Jul 23.

PMID:
31350177
4.

mTORC2 Deficiency Alters the Metabolic Profile of Conventional Dendritic Cells.

Watson AR, Dai H, Zheng Y, Nakano R, Giannou AD, Menk AV, Stolz DB, Delgoffe GM, Thomson AW.

Front Immunol. 2019 Jul 2;10:1451. doi: 10.3389/fimmu.2019.01451. eCollection 2019.

5.

IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell.

Shao L, Hou W, Scharping NE, Vendetti FP, Srivastava R, Roy CN, Menk AV, Wang Y, Chauvin JM, Karukonda P, Thorne SH, Hornung V, Zarour HM, Bakkenist CJ, Delgoffe GM, Sarkar SN.

Cancer Immunol Res. 2019 Aug;7(8):1258-1266. doi: 10.1158/2326-6066.CIR-18-0711. Epub 2019 Jun 25.

PMID:
31239318
6.

The Lysophosphatidylcholine Transporter MFSD2A Is Essential for CD8+ Memory T Cell Maintenance and Secondary Response to Infection.

Piccirillo AR, Hyzny EJ, Beppu LY, Menk AV, Wallace CT, Hawse WF, Buechel HM, Wong BH, Foo JC, Cazenave-Gassiot A, Wenk MR, Delgoffe GM, Watkins SC, Silver DL, D'Cruz LM.

J Immunol. 2019 Jul 1;203(1):117-126. doi: 10.4049/jimmunol.1801585. Epub 2019 May 24.

PMID:
31127034
7.

Tumor-Derived α-Fetoprotein Suppresses Fatty Acid Metabolism and Oxidative Phosphorylation in Dendritic Cells.

Santos PM, Menk AV, Shi J, Tsung A, Delgoffe GM, Butterfield LH.

Cancer Immunol Res. 2019 Jun;7(6):1001-1012. doi: 10.1158/2326-6066.CIR-18-0513. Epub 2019 Apr 15.

PMID:
30988028
8.

IL-17 metabolically reprograms activated fibroblastic reticular cells for proliferation and survival.

Majumder S, Amatya N, Revu S, Jawale CV, Wu D, Rittenhouse N, Menk A, Kupul S, Du F, Raphael I, Bhattacharjee A, Siebenlist U, Hand TW, Delgoffe GM, Poholek AC, Gaffen SL, Biswas PS, McGeachy MJ.

Nat Immunol. 2019 May;20(5):534-545. doi: 10.1038/s41590-019-0367-4. Epub 2019 Apr 8.

9.

Lymphocyte Activation Gene-3 Maintains Mitochondrial and Metabolic Quiescence in Naive CD4+ T Cells.

Previte DM, Martins CP, O'Connor EC, Marre ML, Coudriet GM, Beck NW, Menk AV, Wright RH, Tse HM, Delgoffe GM, Piganelli JD.

Cell Rep. 2019 Apr 2;27(1):129-141.e4. doi: 10.1016/j.celrep.2019.03.004.

10.

Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma.

Najjar YG, Menk AV, Sander C, Rao U, Karunamurthy A, Bhatia R, Zhai S, Kirkwood JM, Delgoffe GM.

JCI Insight. 2019 Mar 7;4(5). pii: 124989. doi: 10.1172/jci.insight.124989. eCollection 2019 Mar 7.

11.

Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted.

Tilstra JS, Avery L, Menk AV, Gordon RA, Smita S, Kane LP, Chikina M, Delgoffe GM, Shlomchik MJ.

J Clin Invest. 2018 Nov 1;128(11):4884-4897. doi: 10.1172/JCI120859. Epub 2018 Sep 24.

12.

ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.

Vendetti FP, Karukonda P, Clump DA, Teo T, Lalonde R, Nugent K, Ballew M, Kiesel BF, Beumer JH, Sarkar SN, Conrads TP, O'Connor MJ, Ferris RL, Tran PT, Delgoffe GM, Bakkenist CJ.

J Clin Invest. 2018 Aug 31;128(9):3926-3940. doi: 10.1172/JCI96519. Epub 2018 Aug 13.

13.

IL-23 and IL-1β Drive Human Th17 Cell Differentiation and Metabolic Reprogramming in Absence of CD28 Costimulation.

Revu S, Wu J, Henkel M, Rittenhouse N, Menk A, Delgoffe GM, Poholek AC, McGeachy MJ.

Cell Rep. 2018 Mar 6;22(10):2642-2653. doi: 10.1016/j.celrep.2018.02.044.

14.

4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses.

Menk AV, Scharping NE, Rivadeneira DB, Calderon MJ, Watson MJ, Dunstane D, Watkins SC, Delgoffe GM.

J Exp Med. 2018 Apr 2;215(4):1091-1100. doi: 10.1084/jem.20171068. Epub 2018 Mar 6.

15.

Early TCR Signaling Induces Rapid Aerobic Glycolysis Enabling Distinct Acute T Cell Effector Functions.

Menk AV, Scharping NE, Moreci RS, Zeng X, Guy C, Salvatore S, Bae H, Xie J, Young HA, Wendell SG, Delgoffe GM.

Cell Rep. 2018 Feb 6;22(6):1509-1521. doi: 10.1016/j.celrep.2018.01.040.

16.

Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.

Rivadeneira DB, Delgoffe GM.

Clin Cancer Res. 2018 Jun 1;24(11):2473-2481. doi: 10.1158/1078-0432.CCR-17-0894. Epub 2018 Jan 31. Review.

17.

Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity.

Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, Horne W, Moskovitz JM, Kolls JK, Sander C, Shuai Y, Normolle DP, Kirkwood JM, Ferris RL, Delgoffe GM, Bruno TC, Workman CJ, Vignali DAA.

Cell. 2017 Jun 1;169(6):1130-1141.e11. doi: 10.1016/j.cell.2017.05.005. Epub 2017 May 25.

18.

Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ Treg cells are a source of tumour-associated Treg cells.

Downs-Canner S, Berkey S, Delgoffe GM, Edwards RP, Curiel T, Odunsi K, Bartlett DL, Obermajer N.

Nat Commun. 2017 Mar 14;8:14649. doi: 10.1038/ncomms14649.

19.

Cutting Edge: Murine Mast Cells Rapidly Modulate Metabolic Pathways Essential for Distinct Effector Functions.

Phong B, Avery L, Menk AV, Delgoffe GM, Kane LP.

J Immunol. 2017 Jan 15;198(2):640-644. doi: 10.4049/jimmunol.1601150. Epub 2016 Dec 14.

20.

Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia.

Scharping NE, Menk AV, Whetstone RD, Zeng X, Delgoffe GM.

Cancer Immunol Res. 2017 Jan;5(1):9-16. doi: 10.1158/2326-6066.CIR-16-0103. Epub 2016 Dec 9.

21.

Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity.

Scharping NE, Delgoffe GM.

Vaccines (Basel). 2016 Dec 6;4(4). pii: E46. Review.

22.

Filling the Tank: Keeping Antitumor T Cells Metabolically Fit for the Long Haul.

Delgoffe GM.

Cancer Immunol Res. 2016 Dec;4(12):1001-1006. Review.

23.

VHL Brings Warburg into the Memory Spotlight.

Delgoffe GM.

Immunity. 2016 Nov 15;45(5):953-955. doi: 10.1016/j.immuni.2016.11.001.

24.

The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction.

Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, Ferris RL, Delgoffe GM.

Immunity. 2016 Sep 20;45(3):701-703. doi: 10.1016/j.immuni.2016.08.009. Epub 2016 Sep 20. No abstract available.

25.

The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction.

Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, Ferris RL, Delgoffe GM.

Immunity. 2016 Aug 16;45(2):374-88. doi: 10.1016/j.immuni.2016.07.009. Epub 2016 Aug 2. Erratum in: Immunity. 2016 Sep 20;45(3):701-703.

26.

Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion.

Bengsch B, Johnson AL, Kurachi M, Odorizzi PM, Pauken KE, Attanasio J, Stelekati E, McLane LM, Paley MA, Delgoffe GM, Wherry EJ.

Immunity. 2016 Aug 16;45(2):358-73. doi: 10.1016/j.immuni.2016.07.008. Epub 2016 Aug 2.

27.

Tumor and T-cell metabolism: new insights into melanoma therapy.

Delgoffe GM.

Clin Adv Hematol Oncol. 2016 Apr;14(4):232-4. No abstract available.

PMID:
27166604
28.

PP2A's restraint of mTOR is critical for T(reg) cell activity.

Delgoffe GM.

Nat Immunol. 2016 May;17(5):478-9. doi: 10.1038/ni.3442. No abstract available.

PMID:
27092798
29.

Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8(+) T cell differentiation.

Pollizzi KN, Sun IH, Patel CH, Lo YC, Oh MH, Waickman AT, Tam AJ, Blosser RL, Wen J, Delgoffe GM, Powell JD.

Nat Immunol. 2016 Jun;17(6):704-11. doi: 10.1038/ni.3438. Epub 2016 Apr 11.

30.

Interleukin-35 Limits Anti-Tumor Immunity.

Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, Beres AJ, Vogel P, Workman CJ, Vignali DA.

Immunity. 2016 Feb 16;44(2):316-29. doi: 10.1016/j.immuni.2016.01.013. Epub 2016 Feb 9.

31.

Feeding an army: The metabolism of T cells in activation, anergy, and exhaustion.

Delgoffe GM, Powell JD.

Mol Immunol. 2015 Dec;68(2 Pt C):492-6. doi: 10.1016/j.molimm.2015.07.026. Review.

32.

mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation.

Pollizzi KN, Patel CH, Sun IH, Oh MH, Waickman AT, Wen J, Delgoffe GM, Powell JD.

J Clin Invest. 2015 May;125(5):2090-108. doi: 10.1172/JCI77746. Epub 2015 Apr 20.

33.

Sugar, fat, and protein: new insights into what T cells crave.

Delgoffe GM, Powell JD.

Curr Opin Immunol. 2015 Apr;33:49-54. doi: 10.1016/j.coi.2015.01.015. Epub 2015 Feb 6. Review.

34.

A Fox of a different color: FoxA1 programs a new regulatory T cell subset.

Delgoffe GM, Vignali DA.

Nat Med. 2014 Mar;20(3):236-7. doi: 10.1038/nm.3493. No abstract available.

PMID:
24603791
35.

STAT heterodimers in immunity: A mixed message or a unique signal?

Delgoffe GM, Vignali DA.

JAKSTAT. 2013 Jan 1;2(1):e23060. doi: 10.4161/jkst.23060. Review.

36.

Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis.

Delgoffe GM, Woo SR, Turnis ME, Gravano DM, Guy C, Overacre AE, Bettini ML, Vogel P, Finkelstein D, Bonnevier J, Workman CJ, Vignali DA.

Nature. 2013 Sep 12;501(7466):252-6. doi: 10.1038/nature12428. Epub 2013 Aug 4.

37.

Identity crisis: it's not just Foxp3 anymore.

Delgoffe GM, Bettini ML, Vignali DA.

Immunity. 2012 Nov 16;37(5):759-61. doi: 10.1016/j.immuni.2012.10.012.

38.

The composition and signaling of the IL-35 receptor are unconventional.

Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, Murray PJ, Vignali DA.

Nat Immunol. 2012 Feb 5;13(3):290-9. doi: 10.1038/ni.2227.

39.

Exploring functional in vivo consequences of the selective genetic ablation of mTOR signaling in T helper lymphocytes.

Delgoffe GM, Powell JD.

Methods Mol Biol. 2012;821:317-27. doi: 10.1007/978-1-61779-430-8_20.

40.

Cutting edge: regulatory T cells do not mediate suppression via programmed cell death pathways.

Szymczak-Workman AL, Delgoffe GM, Green DR, Vignali DA.

J Immunol. 2011 Nov 1;187(9):4416-20. doi: 10.4049/jimmunol.1100548. Epub 2011 Sep 26.

41.

Interpreting mixed signals: the cell's cytokine conundrum.

Delgoffe GM, Murray PJ, Vignali DA.

Curr Opin Immunol. 2011 Oct;23(5):632-8. doi: 10.1016/j.coi.2011.07.013. Epub 2011 Aug 16. Review.

42.

The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2.

Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, Xiao B, Worley PF, Powell JD.

Nat Immunol. 2011 Apr;12(4):295-303. doi: 10.1038/ni.2005. Epub 2011 Feb 27.

43.

The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism.

Powell JD, Delgoffe GM.

Immunity. 2010 Sep 24;33(3):301-11. doi: 10.1016/j.immuni.2010.09.002. Review.

44.

The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation.

Gulen MF, Kang Z, Bulek K, Youzhong W, Kim TW, Chen Y, Altuntas CZ, Sass Bak-Jensen K, McGeachy MJ, Do JS, Xiao H, Delgoffe GM, Min B, Powell JD, Tuohy VK, Cua DJ, Li X.

Immunity. 2010 Jan 29;32(1):54-66. doi: 10.1016/j.immuni.2009.12.003. Epub 2010 Jan 7.

45.

Anergic T cells are metabolically anergic.

Zheng Y, Delgoffe GM, Meyer CF, Chan W, Powell JD.

J Immunol. 2009 Nov 15;183(10):6095-101. doi: 10.4049/jimmunol.0803510. Epub 2009 Oct 19.

46.

mTOR: taking cues from the immune microenvironment.

Delgoffe GM, Powell JD.

Immunology. 2009 Aug;127(4):459-65. doi: 10.1111/j.1365-2567.2009.03125.x. Review.

47.

Enhanced interaction between Hsp90 and raptor regulates mTOR signaling upon T cell activation.

Delgoffe GM, Kole TP, Cotter RJ, Powell JD.

Mol Immunol. 2009 Aug;46(13):2694-8. doi: 10.1016/j.molimm.2009.05.185. Epub 2009 Jul 7.

48.

The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment.

Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, Worley PF, Kozma SC, Powell JD.

Immunity. 2009 Jun 19;30(6):832-44. doi: 10.1016/j.immuni.2009.04.014.

Supplemental Content

Loading ...
Support Center